May 22, 2024

Propelled By The Rise In Waterborne Diseases The global Legionella Testing Market is estimated to be valued at US$ 1,864.7 Mn in 2023

Legionnaires’ disease is a potentially fatal form of pneumonia caused by the Legionella bacteria present in water systems and environments. Legionella testing helps detect the presence of Legionella bacteria, allowing organizations to take preventive measures and reduce the risk of Legionnaires’ disease outbreak. The global legionella testing market involves testing of water samples collected from domestic water supplies, cooling towers, industrial water processes, and others to identify Legionella presence. The global Legionella Testing Market is estimated to be valued at US$ 1,864.7 Mn in 2023 and is expected to exhibit a CAGR of 7.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

The rise in waterborne diseases is a key trend propelling the growth of the legionella testing market. Legionnaires’ disease is a severe form of pneumonia caused by Legionella bacteria. As per the CDC, each year approximately 8,000-18,000 people in the United States get Legionnaires’ disease. The number of reported Legionnaires’ disease cases have doubled in the last 15 years according to the European Centre for Disease Prevention and Control (ECDC). Legionella bacteria thrive in warm water and can spread through water systems. Thus, regular legionella testing helps in mitigating the risk of Legionnaires’ disease outbreak by detecting the presence of Legionella bacteria in water systems. Furthermore, guidelines mandating regular legionella testing in healthcare facilities, hotels, and industrial water processes have boosted the adoption of legionella testing solutions over the years.

SWOT Analysis
Strength: Legionella testing offers higher sensitivity and specificity over traditional culture-based methods. These methods provide rapid results within 2-3 hours which enables prompt implementation of control measures.
Weakness: PCR and immunochromatographic assays require sophisticated equipment and trained personnel, making them less suitable for use in resource-constrained settings. Sample transportation requirements can also pose logistical challenges.
Opportunity: Increasing awareness about Legionnaires’ disease diagnosis and prevention among the public as well as regulatory authorities is driving demand for Legionella testing solutions. Growth in healthcare infrastructure and spending in emerging markets also provides new opportunities.
Threats: Alternative pathogen detection methods that offer a broader testing scope pose competitive threats. Budgetary constraints in cost-sensitive markets may limit testing adoption.

Key Takeaways

The global Legionella testing market is expected to witness high growth over the forecast period. North America currently dominates the market owing to stringent regulatory standards and advanced healthcare infrastructure in the region. The growing elderly population which is more susceptible to Legionnaires’ disease has further accelerated regional market growth.

Key players operating in the Legionella testing market are Boston Scientific Corporation, Argon Medical Devices, Inc., Becton, Dickinson and Company, Cook Medical, B. Braun Melsungen AG, Medtronic Plc., Novo Nordisk A/S, SERAG-WIESSNER GmbH & Co., Smithâ€TMs Medical, Terumo Corporation, Stryker Corporation, and NIPRO Medical Corporation. PCR-based and immunoassay-based are the most widely used technology segments in the market. Continuous technological advancements aimed at improving accuracy, reducing turn-around-time and expanding the detectable scope of pathogens will remain crucial for industry players.

*Note:

  1. Source: Coherent Market Insights, Public sources, Desk research
  2. We have leveraged AI tools to mine information and compile it